Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Effect of a tranexamic acid, kojic acid, and niacinamide containing serum on facial dyschromia: a clinical evaluation
An easy-to-take capsule that is designed for enhanced bioavailability
This finding introduces a potential safety consideration employers may need to weigh when evaluating coverage strategies
#AcuteDecompensation #ACLF #Inflammation #LiverDisease #GENFIT #G1090N *G1090N is an investigational drug candidate.* European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Liver Patients' Association - ELPA Global Liver Institute American Liver Foundation To view or add a comment, sign in Following recent Phase 1 data that provided a solid foundation for advancing G1090N into Phase 2 proof-of-concept studies across the ACLF continuum, explore our latest scientific poster presented at AASLD 2025 to learn more about its active metabolite and earlier body of evidence
US$ 22.38
US$ 26.12
US$ 27.54
US$ 28.02
US$ 25.76
US$ 21.28
